Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: March 27, 2026
Subject: Filing of the Articles of Association as amended at the Annual General Meeting on March 26, 2026.
Business Objects: Research, development, manufacturing, and commercialization of pharmaceutical, medical, and technical products.
Financial Metrics
This filing contains corporate governance documents and does not report financial performance data for the period.
- Revenue, Profit, Cash Flow, Margins: Not provided in this filing.
- Debt and Liquidity: Not provided in this filing.
- Share Capital: DKK 446,500,000 (fully paid up).
- Share Structure:
- A Shares: DKK 107,487,200 (Non-negotiable, 10 votes per DKK 0.01).
- B Shares: DKK 339,012,800 (Negotiable, 1 vote per DKK 0.01).
Material Changes
The filing reflects amendments to the Articles of Association adopted on March 26, 2026. Key structural provisions include:
- Capital Increase Authority: The Board is authorized until April 1, 2028, to increase share capital by up to DKK 44,650,000. This may be done with pre-emptive rights (cash or below market price) or without pre-emptive rights (market price, cash or assets).
- Dividend Policy: A shares receive a priority dividend of 0.5%. B shares receive priority up to 5%. Additional dividends are distributed such that A shares never exceed the percentage rate paid to B shares.
- General Meetings: The Board may convene partially or fully electronic meetings. The Annual General Meeting must be held before the end of April.
- Language: English is the corporate language; documents and meetings are conducted in English with Danish interpretation available.
Guidance, Outlook, and Risks
Management Commentary: The filing does not contain management commentary on business outlook, guidance, or operational risks. It strictly outlines legal and governance frameworks.
Contingencies and Unusual Items:
- Share Transfer Restrictions: A shares are non-negotiable and subject to a right of first refusal by other A shareholders (via the Board) at a price based on the average B share price over the last three months.
- Winding Up: In dissolution, B share capital is covered first at nominal value, followed by A share capital. Remaining assets are distributed proportionally.
- Indemnification: A scheme exists to indemnify Board and Executive Management members for losses incurred during their duties.
Key Facts for Investor Verification
- Verify the current market price of B shares to understand the valuation floor for any potential A share transfers.
- Confirm the Board's utilization of the DKK 44,650,000 capital increase authority granted until April 2028.
- Review the upcoming Annual General Meeting agenda (due before end of April) for specific dividend declarations and board elections.
- Note the dual-class voting structure where A shares carry 10x the voting power of B shares per nominal unit.